Mobile

Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPPIV inhibitor RO0730699 in patients wi...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004528-11

Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPPIV inhibitor RO0730699 in patients with type 2 diabetes

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the doses of RO0730699 which, when compared to placebo, are efficacious, safe and tolerable in patients with type 2 diabetes

Critère d'inclusion

  • Type 2 Diabetes

Liens